🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07468370
Starting soon Observational

Real Time Craniotomy Planning Using Mixed Reality

NCT07468370 · tracked via the Priya Life Science USA tracker
Sponsor
Brainlab AG
Phase
Observational
Started
2026-06
Last updated
2026-03-12

Condition(s) studied

NeurosurgerySurgical PlanningBrain Tumor AdultCraniotomy Tumor Removal Surgery

Investigational drug(s) / intervention(s)

Mixed Reality Glasses/ViewerSurvey using a questionnaire.

Mixed Reality Glasses/Viewer: Mixed reality glasses with 3D viewer used to visualize cranitomy planning environment for incision planning and patient positioning

Survey using a questionnaire.: A survey will be completed by hospital personnel that use the mixed reality environment (glasse and viewer) to evaluate craniotomy planning for participants in the Brain Tumor Group

Study summary

This study is a prospective observational study designed to evaluate the effectiveness of Brainlab's Mixed Reality Viewer in enhancing the accuracy and efficiency of preoperative craniotomy planning. The study will be conducted at a single site with two enrollment groups. Group 1 has a target enrollment of 38 subjects. Group 2 has a target enrollment of 16 subjects. By observing the device's use during standard surgical procedures, we can accurately measure its impact on incision planning accuracy, time efficiency, and overall ease of use compared to traditional neuronavigation systems. This design allows for the collection of both quantitative and qualitative data, providing a robust assessment of the Mixed Reality Viewer's potential to enhance surgical outcome

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Brain Tumor Group Inclusion Criteria: * Diagnosis: Patients diagnosed with a brain tumor requiring surgical intervention. * Age: Adults aged 18 years and older. * Consent: Patients who are able to provide written informed consent and are willing to comply with study procedures. * Preoperative Imaging: Patients who have undergone standard of care preoperative imaging (e.g., MRI, CT) suitable for use with the Brainlab Mixed Reality Viewer. * Surgical Eligibility: Patients deemed eligible for craniotomy based on current clinical standards and the judgment of the attending neurosurgeon. Brain Tumor Group Exclusion Criteria: * Inability to Provide Informed Consent: Subject is unable to provide written informed consent due to cognitive impairment, language barriers, or other reasons that preclude them from understanding the study's requirements. * Emergency Surgery: Subject requires emergency craniotomy where there is insufficient time to perform preoperative planning with the Mixed Reality Viewer. * Concurrent Participation in Other Clinical Trials: Subject is currently enrolled in another clinical trial that could interfere with the results of this study or place additional burdens on the subject. * Unstable Clinical Condition: Subject has a medical condition that is unstable or severe enough to preclude safe participation in the study, as determined by the investigator (e.g., severe cardiac or respiratory conditions). Survey Group Inclusion Criteria: * Hospital Personnel: Includes hospital personnel operating or assisting in the brain tumor resection surgeries where the study device is being utilized on an enrolled subject in the study. This includes the Investigators, Clinical Research Coordinator, OR Nurses, and Residents. * Age: Adults aged 18 years and older. * Consent: Hospital personnel who are able to provide written informed consent and are willing to complete the survey. Survey Group Exclusion Criteria: * Inability to Provide Informed Consent: Hospital personnel is unable to provide written informed consent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Brigham and Women's Hospital, Inc. Boston Massachusetts
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07468370 on ClinicalTrials.gov ↗ ← All trials in the USA